| Flotillin is a novel diagnostic blood marker of Alzheimer’s disease M Abdullah, N Kimura, H Akatsu, Y Hashizume, T Ferdous, T Tachita, ... Journal of Alzheimer's Disease 72 (4), 1165-1176, 2019 | 30 | 2019 |
| Expression, mutation, and methylation of cereblon‐pathway genes at pre‐and post‐lenalidomide treatment in multiple myeloma T Tachita, S Kinoshita, M Ri, S Aoki, A Asano, T Kanamori, T Yoshida, ... Cancer science 111 (4), 1333-1343, 2020 | 20 | 2020 |
| Expression analysis of two SLAM family receptors, SLAMF2 and SLAMF7, in patients with multiple myeloma R Ashour, M Ri, SS Aly, T Yoshida, T Tachita, T Kanamori, S Aoki, ... International Journal of Hematology 110, 69-76, 2019 | 13 | 2019 |
| Exophiala dermatitidis fungemia diagnosed using time-of-flight mass spectrometry during chemotherapy for malignant lymphoma and successful treatment with voriconazole T Yoshida, T Tachita, H Fujinami, Y Oshima, H Sasaki, Y Marumo, ... Internal Medicine 58 (15), 2219-2224, 2019 | 8 | 2019 |
| Newly diagnosed extranodal NK/T-cell lymphoma, nasal type, at the injected left arm after BNT162b2 mRNA COVID-19 vaccination T Tachita, T Takahata, S Yamashita, T Ebina, K Kamata, K Yamagata, ... International Journal of Hematology 118 (4), 503-507, 2023 | 7 | 2023 |
| Impact of chromosomal abnormalities on the efficacy of lenalidomide plus dexamethasone treatment in patients with relapsed/refractory multiple myeloma T Yoshida, M Ri, H Fujinami, Y Oshima, T Tachita, Y Marumo, H Sasaki, ... International Journal of Hematology 110, 228-236, 2019 | 5 | 2019 |
| Volunteer unrelated donor cell‐derived acute myeloid leukemia with RUNX1‐RUNX1T1 S Hagiwara, S Kusumoto, A Ito, A Masaki, K Shiraga, T Tachita, K Hirade, ... EJHaem 2 (2), 285-290, 2021 | 2 | 2021 |
| Genomic analysis of multiple myeloma using targeted capture sequencing in the Japanese cohort T Kanamori, M Sanada, M Ri, H Ueno, D Nishijima, T Yasuda, T Tachita, ... British Journal of Haematology 191 (5), 755-763, 2020 | 2 | 2020 |
| Aberrant tryptophan metabolism leads to unfavorable outcomes in lenalidomide‐treated myeloma patients A Asano, M Ri, A Masaki, Y Maeda, T Tachita, K Hirade, Y Marumo, ... Hematological Oncology 41 (3), 424-433, 2023 | 1 | 2023 |
| Influence of CYP3A5 and ABCB1 polymorphisms on the pharmacokinetics of vincristine in adult patients receiving CHOP therapy J Nakagawa, T Takahata, Y Chen, K Saito, K Kamata, T Tachita, ... Cancer Chemotherapy and Pharmacology 92 (5), 391-398, 2023 | | 2023 |
| P65-1 Clinicopathological feature of T-cell lymphoma in our institute T Takahata, T Tachita, S Yamashita, T Ebina, K Kamata, Y Chen, K Saito, ... Annals of Oncology 33, S537, 2022 | | 2022 |
| PS1367 COMPREHENSIVE GENETIC ANALYSIS OF MULTIPLE MYELOMA IN JAPAN T Kanamori, M Sanada, M Ri, H Ueno, D Nishijima, T Yasuda, S Aoki, ... HemaSphere 3, 624-625, 2019 | | 2019 |
| PF572 ANALYSES OF EXPRESSION LEVELS, MUTATIONS, AND METHYLATION STATUS OF CRBN-RELATED GENES PRE-AND POST-LENALIDOMIDE TREATMENT IN MULTIPLE MYELOMA T Tachita, S Kinoshita, M Ri, S Aoki, A Asano, T Kanamori, H Totani, ... HemaSphere 3 (S1), 238-239, 2019 | | 2019 |
| PB1942 DOES STEPWISE DOSE ESCALATION METHOD OF NILOTINIB FOR CML IMPROVE MR4. 5 AND TREATMENT FREE REMISSION? K Mayama, K Yamaguchi, S Yamashita, T Ebina, T Tachita, K Kamata, ... HemaSphere 3 (S1), 883, 2019 | | 2019 |
| Richter syndrome successfully treated with ibrutinib monotherapy: two case reports H Fujinami, S Kusumoto, A Masaki, Y Ohshima, T Tachita, H Sasaki, ... [Rinsho Ketsueki] The Japanese Journal of Clinical Hematology 60 (10), 1462-1467, 2019 | | 2019 |
